Avenzo Therapeutics, Inc. — Form D
Avenzo Therapeutics, Inc. of SAN DIEGO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2025-09-05. The offering totals $75.0M, of which $47.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-09-05
- Form: D
- Accession: 0001231919-25-000185
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $75.0M
- Amount sold: $47.2M
- Remaining: $27.8M
- Investors: 20
- Date of first sale: 2025-08-22
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-556725
Issuer
- Name: Avenzo Therapeutics, Inc.
- CIK: 0001947742
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 12707 High Bluff Drive, Suite 200, SAN DIEGO, CA, 92130
- Phone: (858) 239-2944
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Athena Countouriotis | Director | San Diego, CA |
| Jakob Dupont, M.D., M.A. | Director | San Diego, CA |
| Simeon George | Director | Redwood City, CA |
| CARL GORDON | Director | SAN DIEGO, CA |
| Judith Li | Director | San Diego, CA |
| Patrick Machado | Director | San Diego, CA |
| Garry Nicholson | Director | San Diego, CA |
| Athena Countouriotis | Executive Officer | San Diego, CA |
| Mohammad Hirmand | Executive Officer | San Diego, CA |
| Scott Lipman | Executive Officer | San Diego, CA |
| Brian Sun | Executive Officer | San Diego, CA |
| Paolo Tombesi | Executive Officer | San Diego, CA |
| Michael Rome | Director | Palm Beach, FL |
Other filings by this issuer (3)
More